NMRD Key Statistics, Chart & Performance
The current stock price of NMRD is 0.1053 USD. In the past month the price decreased by -54.22%. In the past year, price decreased by -94.2%.
NMRD Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 25.11 | 217.86B | ||
| ISRG | INTUITIVE SURGICAL INC | 65.78 | 200.77B | ||
| BSX | BOSTON SCIENTIFIC CORP | 32.32 | 141.35B | ||
| SYK | STRYKER CORP | 26.69 | 134.41B | ||
| BDX | BECTON DICKINSON AND CO | 13.46 | 55.39B | ||
| IDXX | IDEXX LABORATORIES INC | 53.65 | 54.02B | ||
| EW | EDWARDS LIFESCIENCES CORP | 33.17 | 49.47B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 17.87 | 37.36B | ||
| RMD | RESMED INC | 24.33 | 35.16B | ||
| DXCM | DEXCOM INC | 35.68 | 25.89B | ||
| PODD | INSULET CORP | 62.2 | 20.00B | ||
| ZBH | ZIMMER BIOMET HOLDINGS INC | 11.11 | 17.82B |
Related stock screener links
About NMRD
Company Profile
Nemaura Medical, Inc. operates as a holding company. The company is headquartered in New York City, New York and currently employs 36 full-time employees. The company went IPO on 2014-11-04. The firm is commercializing sugarBEAT and proBEAT. The Company, through its operating subsidiaries, performs medical device research and manufacturing of a continuous glucose monitoring system (CGM), sugarBEAT. The sugarBEAT device is a non-invasive, wireless device for use by persons with Type I and Type II diabetes and also be used to screen pre-diabetic patients. The sugarBEAT device extracts from analytes, such as glucose, from the surface of the skin in a non-invasive manner where it is measured using sensors and interpreted using an algorithm. The SugarBEAT works by extracting glucose from the skin into a chamber in the patch that is in direct contact with an electrode-based sensor. The proBEAT combines non-invasive glucose data processed using artificial intelligence and a digital healthcare subscription service.
Company Info
NEMAURA MEDICAL INC
57 W 57th St
New York City NEW YORK 10019 US
CEO: Dewan Fazlul Hoque Chowdhury
Employees: 36
NEMAURA MEDICAL INC / NMRD FAQ
Can you describe the business of NEMAURA MEDICAL INC?
Nemaura Medical, Inc. operates as a holding company. The company is headquartered in New York City, New York and currently employs 36 full-time employees. The company went IPO on 2014-11-04. The firm is commercializing sugarBEAT and proBEAT. The Company, through its operating subsidiaries, performs medical device research and manufacturing of a continuous glucose monitoring system (CGM), sugarBEAT. The sugarBEAT device is a non-invasive, wireless device for use by persons with Type I and Type II diabetes and also be used to screen pre-diabetic patients. The sugarBEAT device extracts from analytes, such as glucose, from the surface of the skin in a non-invasive manner where it is measured using sensors and interpreted using an algorithm. The SugarBEAT works by extracting glucose from the skin into a chamber in the patch that is in direct contact with an electrode-based sensor. The proBEAT combines non-invasive glucose data processed using artificial intelligence and a digital healthcare subscription service.
Can you provide the latest stock price for NEMAURA MEDICAL INC?
The current stock price of NMRD is 0.1053 USD. The price decreased by -17.8% in the last trading session.
What is the dividend status of NEMAURA MEDICAL INC?
NMRD does not pay a dividend.
What is the ChartMill rating of NEMAURA MEDICAL INC stock?
NMRD has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
Where is NEMAURA MEDICAL INC (NMRD) stock traded?
NMRD stock is listed on the Nasdaq exchange.
What is NEMAURA MEDICAL INC worth?
NEMAURA MEDICAL INC (NMRD) has a market capitalization of 3.04M USD. This makes NMRD a Nano Cap stock.
Can you provide the ownership details for NMRD stock?
You can find the ownership structure of NEMAURA MEDICAL INC (NMRD) on the Ownership tab.
NMRD Technical Analysis
NMRD Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to NMRD. Both the profitability and financial health of NMRD have multiple concerns.
NMRD Financial Highlights
Over the last trailing twelve months NMRD reported a non-GAAP Earnings per Share(EPS) of -0.39. The EPS increased by 39.06% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -114.35% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
NMRD Forecast & Estimates
7 analysts have analysed NMRD and the average price target is 8.67 USD. This implies a price increase of 8133.62% is expected in the next year compared to the current price of 0.1053.
For the next year, analysts expect an EPS growth of 42.95% and a revenue growth 43.63% for NMRD